Table 3 Clinical-pathological prognostic features of disease
From: Detection methods predict differences in biology and survival in breast cancer patients
Prevalent (n = 76) vs. Symptomatic (n = 130) | P value | OR adjusted by tumor size | |
|---|---|---|---|
Mean age | 56.8 ± 0.65 vs. 56.3 ± 1.14 | N.S. | 1.01 (0.98-1.03) |
Mean size (cm) | 1.64 ± 0.15 vs. 2.68 ± 0.15 | p < 0.001 | -- |
Lymph node positive | 25% vs. 48.5% | p < 0.001 | 0.54 (0.27-1.08) |
Poorly differentiated tumors | 32.1% vs. 39.7% | N.S. | 0.55 (0.29-1.04) |
ER positive | 87.5% vs. 57.4% | p < 0.001 | 4.56 (1.98-10.52) |
PR positive | 70.3% vs. 36.4% | p < 0.001 | 3.65 (1.88-7.08) |
In situ carcinomas | 13% vs. 1.5% | p < 0.001 | 8.30 (1.70-40.31) |
Apoptosis | 42.5% vs. 38.5% | N.S. | 1.45 (0.67-3.16) |
Bcl-2 | 75.4% vs. 62.7% | N.S. | 1.52 (0.75-3.06) |
c-erb-B2 | 7.4% vs. 26.3% | p < 0.01 | 0.59 (0.31-0.90) |
Ki67 | 38.5 vs. 52.5% | N.S. | 0.64 (0.34-1.22) |
Delay Diagnosis-treatment (>30 days) | 64.5% vs. 55% | N.S. | 1.51 (0.81-2.81) |